Boston Scientific (BSX) Receivables (2009 - 2026)

Boston Scientific (BSX) has 18 years of Receivables data on file, last reported at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 12.4% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (up 12.4% YoY), and the FY2025 full-year result was $3.1 billion, up 14.66% from the prior year.
• Receivables slipped to $3.0 billion in Q1 2026, from $3.1 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.1 billion in Q4 2025 to a low of $1.9 billion in Q1 2022.
• A 5-year average of $2.4 billion and a median of $2.4 billion in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables increased 5.79% in 2023 and grew 19.7% in 2024, its largest moves.
• Tracing BSX's Receivables over 5 years: stood at $2.1 billion in 2022, then advanced by 7.17% to $2.2 billion in 2023, then rose by 19.7% to $2.7 billion in 2024, then advanced by 14.66% to $3.1 billion in 2025, then decreased by 1.01% to $3.0 billion in 2026.
• Business Quant data shows BSX's Receivables at $3.0 billion in Q1 2026, $3.1 billion in Q4 2025, and $2.8 billion in Q3 2025.